相关实验视频

Updated: Jun 22, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

CTLA-4沉默可以促进肝细胞的抗瘤作用

Amirhossein Mardi^1,2,3, Mahsan Alizadeh⁴, Amir Shahabaddin Abdolalizadeh⁴

¹Student Research Committee, Tabriz University of Medical Science, Tabriz, Iran.

Medical oncology (Northwood, London, England)

|July 2, 2024

概括

用siRNA抑制CTLA-4会抑制肝癌细胞的生长和迁移,并诱导细胞亡. 这表明CTLA-4siRNA是肝癌的潜在治疗方法.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

免疫检查点封锁在肝癌治疗中显示出前景.
细胞毒性T-淋巴细胞相关蛋白4 (CTLA-4) 是一个关键的免疫检查点目标.

研究的目的:

研究CTLA-4特异性siRNA在肝癌中的治疗潜力.
评估CTLA-4沉默对HepG2细胞增殖,细胞周期,迁移和亡的影响.

主要方法:

通过电穿孔,HepG2细胞被CTLA-4特定的siRNA感染.
细胞活力,增殖,细胞周期,细胞亡和迁移被分析使用MTT试验,流细胞计和伤口愈合试验.
使用qRT-PCR量化CTLA-4,c-Myc,Ki-67,BCL-2,BAX,caspase-9和MMPs的基因表达水平.

主要成果:

特定于CTLA-4的siRNA显著降低了HepG2细胞中的CTLA-4基因表达.
沉默CTLA-4抑制了细胞增殖和迁移,并诱导了细胞亡.
CTLA-4 siRNA转染导致G2阶段细胞循环停止和关键调节基因 (c-Myc,Ki-67,BCL-2,BAX,caspase-9,MMPs) 的改变表达.

结论:

特定于CTLA-4的siRNA在肝癌细胞上显示出显著的抗癌作用.
用siRNA准CTLA-4代表了肝癌治疗的有前途的治疗策略.

关键词:

在 CTLA-4 中.这就是为什么HePG2是HePG2.肝细胞癌是肝细胞癌.siRNA 是一个RNA.

更多相关视频

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.